CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 107 enrolled
Drug / intervention
MetFORMIN 500 Mg Oral Tablet +1 moredrug
Likely dose
MetFORMIN 500 Mg Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05840068
NCT05840068Phase 4Completed
CompareCT.gov

Metformin Effect as a Chemotherapeutic Adjuvant on Level of IGF in Non-diabetic Breast Cancer Patients

Beni-Suef University·interventional·Posted May 3, 2023·Updated May 3, 2023

In Brief

A Phase 4 clinical trial evaluating MetFORMIN 500 Mg Oral Tablet and Chemotherapy for Breast Cancer Female. Completed, enrolled 107 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the impact of metformin as an adjuvant to chemotherapy on IGF levels in both progressing and non progressing cases of metastatic breast cancer in female patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Female
CountriesEgypt
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMay 3, 2023
Enrollment StartJun 1, 2020
Primary CompletionJul 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.2 years ago

Interventions

MetFORMIN 500 Mg Oral Tabletdrug

MetFORMIN 500 Mg Oral Tablet

Chemotherapydrug

The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).